Therapeutic use of CPG oligodeoxynucleotide for skin disease

Details Therapeutic use of CPG oligodeoxynucleotide for skin disease Therapeutic use of CPG oligodeoxynucleotide for skin disease

2011-05-03

2011-05-03

Ton, Thaian N (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100

Reexamination Certificate

active

07935678

ABSTRACT:
Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.

REFERENCES:
patent: 4458066 (1984-07-01), Carauthers et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 5023243 (1991-06-01), Tullis
patent: 2003/0233675 (2003-12-01), Cao et al.
patent: 2007/0015271 (2007-01-01), Rosen et al.
patent: 0092574 (1992-04-01), None
patent: 1998/029124 (1998-07-01), None
patent: 2001/093905 (2001-12-01), None
patent: 2004/078772 (2004-09-01), None
Najar and Dutz. J Invest Derm 128:2204-2210, 2008.
Hussain and Kline. J Invest Dermatol Symp Proc 9:23-28, 2004.
Tokura. J Dermatol Sci 58:1-7, 2010.
Balles et al. J Immunol 167:4878-4886, 2001.
Immune Response definition printout from http://dictionary.reference.com/browse/immune+response, printed out Jul. 28, 2010, p. 1.
Gilkeson, GS. et al., Induction of Cross-Reactive Anti-dsDNA Antibodies in Preautoimmune NZB/NZW Mice by Immunization with Bacterial DNA, J. Clin. Invest., 1995, 95:1398-1402.
Krieg, AM. et al., CpG motifs in bacterial DNA trigger direct B-cell activation, Nature 374:546-549, 1995.
Akdis, CA. “Immune regulation in atopic dermatitis ,” Curr Opin Immunol., 2000 12:641-646.
Krieg, AM. “CpG Motifs in Bacterial DNA and Their Immune Effects,” Annual Review Immunol., 2002, 20: 709-760.
Warren, TL et al.,“APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells1,” J. Immunol., 2000, 165:6244-6251.
Kwon, HJ. et al., “NF-KB-dependellt regulation of tumor necrosis factor-C′L gene expression by CpG oligodeoxynucleotides,” Biochem. Biophys. Res. Commun, 2003, 311:129-138.
Lee, KW. et al.,“CG sequence- and phosphorothioate backbone modification-dependent activation of the NF-KB-responsive gene expression by CpG-oligodeoxynucleotides in human RPMI 8226 B cells,” Mol. Immunol, 2004, 41:955-964.
Deng GM et al., “The features of arthritis induced by CpG motifs in bacterial DNA,” Arthritis & Rheumatisum, 2000, 43 (2):356-364.
Masayuki Miayta et al., “Unmethylated Oligo-DNA Containing CpG Motifs Aggravates Collagen-Induced Arthritis in Mice,” Arthritis & Rheumatisum, 43(11):2578-2582, 2000.
Tanaka, T. et al., “An Antisense Oligonucleotide Complementary to a Sequence in I′y2b Increases 3′2b Germllne Transcripts, Stimulates B Cell DNA Synthesis, and Inhibits Immunoglobulin Secretion,” J Exp. Med. 1992, 75:597-607.
Hans-Joachim Anders et al., “Activation of toll-like receptor-9 induces, progression of renal disease in MRL-Fas(Ipr) mice,” The FASEB Journal express article 10. 1096/fj. 03-0646fje. published online Jan. 20, 2004.
Tsunoda I. et al., “Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA.,” Brain Pathol. 1999, 9(3):481-493.
Bachmaier K. et al., “Chlamydia Infections and Heart Disease Linked Through Antigenic Mimicry,” Science, 1999, 283(5406):1335-1339.
D'Andrea A et al., “Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells,” J. Exp. Med., 1992, 176:1387.
Sato T et al., Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization, Science 1996, 273:352-354.
Shu U et al., “Activated T cells induce interleukin-12 production by monocytes via CD4O-CD40 ligand interaction,” Eur. J. Immunol., 1995, 25:1125-1128.
Cella M et al.,“Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation,” J. Exp. Med., 1996, 184:747-752.
Chan SH et al., “Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers,” J. Exp. Med., 1991, 173:869-879.
Neumann C., et al., “Comparative analysis of the frequency of house dust mite specific and nonspecific Th1 and Th2 cells in skin lesions and peripheral blood of patients with atopic dermatitis,” J Mol Med., 74: 401-406, 1996.
Aiba S., et al., “Alteration in the production of IL-10 and IL-12 and aberrant expression of CD23, CD83 and CD86 by monocytes or monocyte-derived dendritic cells from atopic dermatitis patients,” Exp Dermatol., 2003, 12: 86-95.
Nilsson C., et al.,“Low numbers of interleukin-12-producing cord blood mononuclear cells and immunoglobulin E sensitization in early childhood.,” Clin Exp Allergy., 2004, 34: 373-380.
Katakura, T., et al., “A combination therapy using IL-12 and soluble IL-4 receptor on herpes simplex virus Type 1 infection in a human-SCID chimera model of thermal injury,” Clin. Immunol. 2002, 105:363-370.
Hengge U. R., et al., “Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum,” Br. J. Dermatol., 2003, 149:15-19.
Arany I., et al., “Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%,”Antiviral Res., 1999, 43: 55-63.
Rook AH., et al “The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma,” Ann. N. Y. Acad. Sci., 1996, 795:310-318.
Gollob, JA., et al.,“Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma,” J. Clin. Oncol., 2003, 21:2564-2573.
Trinchieri G., et al., “Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity,” Annu Rev Immunol., 1995, 13: 251-276.
Krepler C., et al., “CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model,” J. Invest Dermatol., 2004, 122: 387-391.
Vestergaard, C., et al., Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions, J Clin Invest 104:1907-1105, 1999.
Matsuo, R., et al., “Interleukin-12 protects thermally injured mice from herpes simplex virus type 1 infection,” 1996, 59:623-630.

Affiliated with

Also associated with

Rating

Therapeutic use of CPG oligodeoxynucleotide for skin disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic use of CPG oligodeoxynucleotide for skin disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of CPG oligodeoxynucleotide for skin disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2699598